<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Law - KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</title>
	<atom:link href="https://www.kg-legal.eu/info/tag/pharmaceutical-law/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.kg-legal.eu/info/tag/pharmaceutical-law/</link>
	<description>KIELTYKA GLADKOWSKI LEGAL &#124; CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</description>
	<lastBuildDate>Mon, 12 Oct 2026 12:01:45 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	
	<item>
		<title>Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective-2/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective-2/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Mon, 12 Oct 2026 12:01:44 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[EU Regulatory Law]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[Health Claims]]></category>
		<category><![CDATA[HealthTech]]></category>
		<category><![CDATA[Life Sciences]]></category>
		<category><![CDATA[Longevity]]></category>
		<category><![CDATA[Longevity Washing]]></category>
		<category><![CDATA[Novel Foods]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8961</guid>

					<description><![CDATA[<p>Publication date: October 12, 2026 I. Introduction The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective-2/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: October 12, 2026</mark></strong></p>



<h2 class="wp-block-heading">I. Introduction</h2>



<p>The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.<a href="#_ftn1" id="_ftnref1">[1]</a> Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.</p>



<span id="more-8961"></span>



<p>The gap between an enormous market and a non-existent legal definition is precisely where legal risk accumulates. Where there is no definition, there is classification risk, claims risk, and enforcement risk. There is also a phenomenon that this article, borrowing from the vocabulary of environmental marketing, calls “longevity washing.”</p>



<p>This article examines the longevity industry through the lens of EU regulatory law. The EU framework governs a market of some 450 million consumers and, because it is horizontal, sector-specific, and increasingly enforcement-oriented, it offers a useful point of comparison for practitioners in the United States, Asia, and Latin America. Part II explains why “longevity” is not a legal category and introduces the borderline-product problem that follows from that fact. Part III develops the concept of longevity washing and its consumer-facing, unfair-commercial-practice, and investor-facing dimensions. Part IV addresses the regulation of artificial intelligence in longevity research and diagnostics, including the revised timeline of the AI Act, the position of the European Medicines Agency on AI in the medicinal-product lifecycle, and the data-protection architecture formed by the GDPR and the European Health Data Space. Part V maps the sectoral “hot spots” across pharmaceuticals, medical devices, cosmetics, and food supplements. Part VI draws conclusions for practitioners.</p>



<h1 class="wp-block-heading">II. “Longevity” in the Eyes of the Law: The Borderline-Product Problem</h1>



<p>In EU regulatory law, aging is not a disease. The European Medicines Agency has never approved a medicinal product with “aging” as a therapeutic indication, and under Directive 2001/83/EC a medicinal product is defined by reference to the treatment or prevention of disease or the restoration, correction, or modification of physiological functions.<a href="#_ftn2" id="_ftnref2">[2]</a> The position in the United States is comparable. The long-running debate around the Targeting Aging with Metformin (TAME) trial illustrates the point: its designers had to negotiate a trial protocol with the Food and Drug Administration that targets aging indirectly, through a composite of age-related diseases, precisely because “aging” itself is not an approvable indication.<a href="#_ftn3" id="_ftnref3">[3]</a></p>



<p>The consequence is profound. A company cannot lawfully market a product “to treat aging.” The entire longevity industry therefore operates in the space of indirect claims: “supports healthy aging,” “promotes cellular health,” “extends healthspan.” Each of those phrases pushes the product toward one of several very different regulatory regimes.</p>



<p>This is the borderline-product problem, and it is the single most important legal concept in the sector. The same molecule – an NAD precursor, for example – may be: a medicinal product, if it is presented as treating or preventing disease or exerts a significant pharmacological, immunological, or metabolic effect; a food supplement under Directive 2002/46/EC;<a href="#_ftn4" id="_ftnref4">[4]</a> a novel food requiring pre-market authorisation under Regulation (EU) 2015/2283;<a href="#_ftn5" id="_ftnref5">[5]</a> a cosmetic under Regulation (EC) No 1223/2009, if applied to the skin with a claim limited to appearance;<a href="#_ftn6" id="_ftnref6">[6]</a> or a medical device. The last category is broader than it may appear: since the Medical Device Regulation (MDR) came into application, products listed in its Annex XVI – dermal fillers, certain energy-based aesthetic equipment – are regulated as devices even where they have no medical purpose at all.<a href="#_ftn7" id="_ftnref7">[7]</a></p>



<p>Classification does not follow the label a company chooses. It follows presentation, composition, and route of administration. The Court of Justice of the European Union has held for four decades that a product is a medicinal product “by presentation” where it is described or recommended as having properties for treating or preventing disease, irrespective of whether it actually has those properties; and that classification “by function” turns on a case-by-case scientific assessment of the product’s actual pharmacological, immunological, or metabolic action, not on the manufacturer’s intention.<a href="#_ftn8" id="_ftnref8">[8]</a> Marketing language alone can therefore reclassify a product and, with it, the entire compliance burden: marketing authorisation, good manufacturing practice, pharmacovigilance, and advertising restrictions.</p>



<p>When a client says “we are a longevity company,” the first question counsel should ask is: <em>which regime are you actually in?</em> “Longevity” is a marketing word. The law knows only medicines, devices, foods, and cosmetics.</p>



<h1 class="wp-block-heading">III. Longevity Washing: When the Claim Outruns the Science</h1>



<p>Greenwashing – claiming environmental virtue one does not have – is a familiar concept. Longevity washing is its younger sibling: labelling a product, a clinic, a research programme, or an entire company as “longevity-focused” when the science, the indication, or the business model does not support that description. The practice matters legally for three reasons.</p>



<h2 class="wp-block-heading"><em>A. Consumer-Facing Claims</em></h2>



<p>Under the Health Claims Regulation, any health claim made on a food – and food supplements are foods – must be specifically authorised and listed in the EU register.<a href="#_ftn9" id="_ftnref9">[9]</a> Claims such as “slows aging,” “supports cellular repair,” or “extends lifespan” are not authorised health claims. National authorities in the EU and the United Kingdom have treated phrases such as “cellular repair” and even “healthy aging” as impermissible where they imply a physiological mechanism or a reduction of disease risk. A substantial part of the longevity supplement market is thus operating with claims that would not survive enforcement scrutiny.</p>



<h2 class="wp-block-heading"><em>B. Unfair Commercial Practices and the Greenwashing Template</em></h2>



<p>The second layer is the general prohibition of misleading commercial practices under the Unfair Commercial Practices Directive (UCPD).<a href="#_ftn10" id="_ftnref10">[10]</a> Here the EU has recently built an entire enforcement architecture against greenwashing that repays close study by anyone advising on health claims. The Empowering Consumers for the Green Transition Directive amends the UCPD to prohibit generic environmental claims – “eco-friendly,” “climate-neutral” – unless the trader can demonstrate recognised excellent environmental performance, and it adds a series of specific greenwashing practices to the UCPD’s blacklist. Its provisions apply across the Union from 27 September 2026.<a href="#_ftn11" id="_ftnref11">[11]</a></p>



<p>The Directive should be read as a template. If “climate-neutral” now requires substantiation, it is a very short doctrinal step for regulators and courts to demand the same of “clinically proven to slow biological aging.” The methodology of anti-greenwashing enforcement – generic claim, absence of substantiation, misleading omission – maps directly onto longevity claims. The UCPD’s general clauses on misleading actions and omissions already provide the legal basis; what the green-claims reform supplies is a worked example of how those clauses can be operationalised against vague virtue-signalling.</p>



<h2 class="wp-block-heading"><em>C. Investor-Facing Washing</em></h2>



<p>The third dimension is of particular relevance to transactional lawyers. Start-ups increasingly brand themselves as “longevity biotech” because that is where the capital is, even when the underlying asset is a conventional dermatology product or a wellness application. For investors, this creates due-diligence risk: is the “longevity platform” in fact a regulated medicinal pipeline, with all the timeline and cost that implies, or a supplement business one enforcement letter away from relabelling? Misclassification discovered after investment is a valuation event. For the company, aggressive longevity framing in fundraising materials can generate liability under securities and misrepresentation rules in multiple jurisdictions. In due diligence on a longevity start-up, the regulatory classification memorandum is not an annex to the deal; it <em>is</em> the deal.</p>



<h1 class="wp-block-heading">IV. Artificial Intelligence in Longevity Research and Diagnostics</h1>



<p>The longevity field is arguably the most AI-dependent sector in the life sciences, for a simple reason: aging is not one target but thousands of interacting biological processes. A geroprotective drug cannot be designed the way an antibiotic is designed. The entire aging phenotype must be modelled, and that means machine learning on large multi-omic datasets. AI is not an add-on in longevity; it is the core methodology. That raises three distinct regulatory questions under EU law.</p>



<h2 class="wp-block-heading"><em>A. The AI Act</em></h2>



<p>Regulation (EU) 2024/1689, the AI Act, is the most comprehensive horizontal AI regulation in force anywhere and applies to almost every AI system used in the longevity value chain.<a href="#_ftn12" id="_ftnref12">[12]</a> It adopts a risk-based structure – prohibited practices, high-risk systems, transparency obligations, and minimal-risk systems – and the critical category for this sector is high-risk. An AI system that is itself a medical device, or a safety component of one, under the MDR or the In Vitro Diagnostic Regulation, and that is subject to third-party conformity assessment under those instruments, is high-risk under Article 6(1) and Annex I of the AI Act.<a href="#_ftn13" id="_ftnref13">[13]</a> This captures, for example, an AI tool that estimates a patient’s “biological age” from a blood panel and uses that estimate to guide a clinical intervention; an AI-driven diagnostic that predicts age-related disease risk; and the software layer of many longevity-clinic platforms once it makes a diagnostic or prognostic claim.</p>



<p>High-risk status is not a prohibition; it is a compliance regime. It requires a risk-management system, data governance with representative and bias-tested training data, technical documentation, logging, human oversight, transparency to deployers, accuracy, robustness and cybersecurity, a conformity assessment, and post-market monitoring.<a href="#_ftn14" id="_ftnref14">[14]</a> For most longevity start-ups this is a wholly new compliance layer on top of MDR conformity assessment, and the two must be coordinated.</p>



<p>The timeline has recently changed, and practitioners should update their advice accordingly. The original AI Act applied the high-risk obligations from 2 August 2026 for stand-alone systems listed in Annex III and from 2 August 2027 for AI embedded in products covered by Annex I, including medical devices. The Digital Omnibus on AI, adopted as Regulation (EU) 2026/1744 and in force since 27 July 2026, defers those dates to 2 December 2027 and 2 August 2028 respectively.<a href="#_ftn15" id="_ftnref15">[15]</a> The deferral does not lighten the substantive regime; the prohibitions in Article 5, the obligations of providers of general-purpose AI models, and the transparency obligations of Article 50 (which apply from 2 August 2026) are unaffected. For longevity companies whose AI is a medical device, the practical effect is a compliance window of roughly two years, during which harmonised standards and notified-body capacity are expected to mature. The window is an opportunity to design AI Act compliance into the MDR technical file from the outset rather than to defer the exercise.</p>



<h2 class="wp-block-heading"><em>B. AI in Drug Discovery and the European Medicines Agency</em></h2>



<p>The position for drug discovery is more nuanced. An AI model used purely internally to identify candidate molecules – the classic “AI for drug discovery” use case that dominates longevity-biotech pitch decks – is generally not, in itself, a high-risk AI system under the AI Act, because it does not make or materially influence decisions about individual patients. The regulatory question shifts instead to the European Medicines Agency. The EMA’s Reflection Paper on the use of AI in the medicinal product lifecycle sets out the Agency’s expectations from discovery through pharmacovigilance.<a href="#_ftn16" id="_ftnref16">[16]</a> Its core message is that the burden of proof rests on the sponsor to demonstrate that the AI model is fit for its regulatory purpose. That entails documented data provenance, model validation, a degree of explainability appropriate to the stage of development, and lifecycle management of the model itself.</p>



<p>If a longevity company tells its investors that “our AI discovered this molecule,” the regulator will eventually ask to see the model, the training data, and the validation. Vague AI claims in fundraising materials do not survive regulatory scrutiny and, increasingly, do not survive investor due diligence either.</p>



<h2 class="wp-block-heading"><em>C. Data: The GDPR and the European Health Data Space</em></h2>



<p>The third question concerns data, and it is here that longevity becomes uniquely difficult. Aging research is inherently longitudinal and multi-omic: genomic, epigenetic, and proteomic data, wearable data, and medical records, ideally across decades. Under the General Data Protection Regulation this is special-category data – health, genetic, and biometric data – and the available lawful bases are narrow.<a href="#_ftn17" id="_ftnref17">[17]</a> The scientific-research provisions of Article 9(2)(j) and Article 89 assist, but they are implemented differently in each Member State, which produces real fragmentation for pan-European longevity cohorts.</p>



<p>The European Health Data Space Regulation adds a second layer.<a id="_ftnref18" href="#_ftn18">[18]</a> It creates, for the first time, a mandatory EU-wide framework for the secondary use of electronic health data, administered by health-data-access bodies in each Member State. For longevity research the EHDS is potentially transformative, because it opens access to population-scale health data for research purposes. It also imposes strict conditions: purpose limitation, processing only within secure processing environments, a prohibition on re-identification, and specific prohibitions on using the data for advertising or marketing, for decisions detrimental to individuals such as insurance or employment decisions, or for developing products harmful to health.<a id="_ftnref19" href="#_ftn19">[19]</a> The secondary-use chapter applies from March 2029 for most data categories, but the lead time is short in the context of longitudinal cohorts. Longevity companies that intend to monetise health data – and many do – should be mapping their data flows against the EHDS regime now.</p>



<h1 class="wp-block-heading">V. Sector-by-Sector Regulatory Hot Spots</h1>



<p>Four sectoral silos together make up the longevity industry, and the same start-up frequently straddles two or three of them without realising it. In each silo, specific “hot spots” – advertising, manufacturing standards, registration, and market withdrawal – recur in practice.</p>



<h2 class="wp-block-heading"><em>A. Pharmaceuticals</em></h2>



<p>True longevity drugs – rapamycin analogues, senolytics, geroprotectors – sit squarely within Directive 2001/83/EC and its implementing rules, and will continue to do so under the new pharmaceutical package once it applies. Three practical hot spots stand out. First, off-label prescribing of rapamycin and metformin for longevity indications is widespread in private clinics across Europe. Off-label prescribing as such is a matter of clinical freedom, but off-label <em>promotion</em> by or on behalf of the marketing-authorisation holder is prohibited: advertising must conform to the summary of product characteristics, and advertising of unauthorised products or indications is not permitted.<a href="#_ftn20" id="_ftnref20">[20]</a> Longevity clinics are increasingly the vehicle through which promotional messaging reaches patients, and enforcement authorities have begun to take notice. Second, good manufacturing practice: anything presented as a medicine must be manufactured under an EU manufacturing authorisation and EU GMP, with qualified persons and full traceability; compounding pharmacies producing “longevity peptides” have become a significant enforcement target. Third, unlicensed importation: a large part of the longevity-peptide market operates through personal importation and grey channels, and customs enforcement across the EU has visibly tightened.</p>



<h2 class="wp-block-heading"><em>B. Medical Devices</em></h2>



<p>The MDR has fundamentally reshaped this space. Aesthetic devices – dermal fillers, energy-based devices used in longevity clinics, at-home devices marketed for “cellular rejuvenation” – are caught by Annex XVI even without a medical purpose. Three hot spots follow. Classification: many longevity wearables and applications become software as a medical device once they make a diagnostic or prognostic claim. Advertising: Article 7 of the MDR prohibits misleading claims and specifically prohibits ascribing to a device functions and properties it does not have, which operates in practice as a codified anti-washing rule for devices.<a href="#_ftn21" id="_ftnref21">[21]</a> Registration and vigilance: the first four modules of the EUDAMED database – actor registration, UDI/device registration, notified bodies and certificates, and market surveillance – have been mandatory since 28 May 2026, with legacy devices to be registered by 28 November 2026; the vigilance module is not yet mandatory, so serious incidents and field safety corrective actions continue to be reported to national competent authorities.<a href="#_ftn22" id="_ftnref22">[22]</a> Market withdrawals happen: a device sold as a “cellular biomarker analyser” without valid clinical evidence can be removed from the market by any national competent authority, and the MDR’s market-surveillance coordination means that one withdrawal can cascade across the Union.</p>



<h2 class="wp-block-heading"><em>C. Cosmetics and Aesthetic Products</em></h2>



<p>The Cosmetics Regulation governs anti-aging creams, serums, and topical actives. Two hot spots dominate. The first is the Product Information File: the responsible person must hold a complete file including a safety assessment and substantiation of every claim. The second is the Claims Regulation, Commission Regulation (EU) No 655/2013, with its six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making.<a href="#_ftn23" id="_ftnref23">[23]</a> A claim such as “reverses skin aging at the cellular level” fails the evidential-support criterion unless a robust dossier stands behind it. Enforcement is largely national, but the Cosmetic Products Notification Portal is EU-wide, and non-compliant products are routinely notified through the Safety Gate rapid-alert system.</p>



<h2 class="wp-block-heading"><em>D. Food Supplements and Novel Foods</em></h2>



<p>It is in the food and supplement space that the longevity industry is most creative and most exposed. Directive 2002/46/EC governs vitamins and minerals in supplements; everything else falls under the general food law of Regulation (EC) No 178/2002<a href="#_ftn24" id="_ftnref24">[24]</a> and, critically, the Novel Food Regulation. Nicotinamide mononucleotide (NMN), one of the most heavily marketed longevity molecules, is the paradigmatic case. NMN is treated as a novel food in the EU, which means it cannot lawfully be placed on the market as a supplement without pre-market authorisation by the Commission following an EFSA safety assessment. Nicotinamide riboside received such an authorisation in 2020.<a href="#_ftn25" id="_ftnref25">[25]</a> NMN has not – although the picture is now moving. In March 2026 EFSA’s NDA Panel adopted a positive opinion on the safety of β-NMN in food supplements at up to 300 mg per day for adults, and the opinion was published in May 2026.<a href="#_ftn26" id="_ftnref26">[26]</a> An EFSA opinion is a scientific assessment, not an authorisation; the Commission must still adopt an implementing act adding NMN to the Union list, and where the applicant has requested data protection the authorisation will initially be proprietary to that applicant’s specification. Until that act is adopted, NMN products on the shelves of European longevity clinics remain unauthorised novel foods. That is not a grey area; it is a non-compliant market operating in plain sight, and it is the kind of enforcement pipeline that eventually produces high-profile withdrawal actions. Once the Health Claims Regulation is added to the picture, the conclusion is unavoidable: the food and supplement leg of the longevity industry is the most legally exposed part of the entire sector.</p>



<h1 class="wp-block-heading">VI. Conclusions</h1>



<p>The longevity industry is a genuine scientific and commercial phenomenon, and much of the underlying research is serious. But lawyers advising companies, investors, clinicians, and, increasingly, regulators in this space must see it clearly: “longevity” is not a legal category. It is a marketing frame layered on top of four very different regulatory regimes. Three practical conclusions follow for anyone whose product touches European consumers.</p>



<p>First, always begin with classification. The word “longevity” conveys nothing about the applicable regime. Ask what the product is, how it is presented, and what it does, and let the regulatory regime follow from those answers.</p>



<p>Second, treat longevity claims the way green claims are now treated. The direction of enforcement is unmistakable. The Empowering Consumers for the Green Transition Directive, applicable from 27 September 2026, gives regulators a sharpened toolkit that will, sooner or later, be pointed at health and wellness claims. Substantiation is no longer optional.</p>



<p>Third, integrate AI Act compliance with sectoral compliance from the outset. For any longevity venture using AI in diagnostics or patient-facing decision support, the AI Act, the MDR, and the GDPR, soon joined by the European Health Data Space, form a single interlocking compliance architecture. The deferral of the AI Act’s high-risk obligations to 2027 and 2028 is a design window, not a reprieve. Retrofitting is expensive; designing for compliance is not.</p>



<p>The longevity industry will keep growing, and regulators will keep catching up. The lawyers who understand both the science and the sectoral map will be the ones clients call first.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a> Longevity economy estimates vary widely by definition; see, e.g., the periodic longevity-market reports of Bank of America Global Research and McKinsey Health Institute. The figure is offered here as an order of magnitude, not a precise valuation.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a> Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, art. 1(2), 2001 O.J. (L 311) 67 [hereinafter Directive 2001/83]. At the time of writing, the new EU pharmaceutical package (a new directive on the Union code for medicinal products for human use and a new regulation on Union authorisation procedures) has been politically agreed and is in the final stage of formal adoption; the substantive rules discussed here are carried over into the new framework, which will apply after a transitional period of approximately two years from entry into force.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a> See Nir Barzilai et al., Metformin as a Tool to Target Aging, 23 Cell Metabolism 1060 (2016) (describing the design of the Targeting Aging with Metformin (TAME) trial around a composite of age-related diseases).</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the Approximation of the Laws of the Member States Relating to Food Supplements, 2002 O.J. (L 183) 51.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a> Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on Novel Foods, 2015 O.J. (L 327) 1 [hereinafter Novel Food Regulation].</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a> Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on Cosmetic Products, 2009 O.J. (L 342) 59 [hereinafter Cosmetics Regulation].</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a> Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Annex XVI, 2017 O.J. (L 117) 1 [hereinafter MDR]; Commission Implementing Regulation (EU) 2022/2346 of 1 December 2022 Laying Down Common Specifications for the Groups of Products Without an Intended Medical Purpose Listed in Annex XVI, 2022 O.J. (L 311) 60.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a> Case 227/82, Van Bennekom, ECLI:EU:C:1983:354 (establishing that a product is a medicinal product “by presentation” where it is described or recommended as having therapeutic or prophylactic properties, irrespective of its actual efficacy); Case C-319/05, Comm’n v. Germany, ECLI:EU:C:2007:678 (garlic capsules); Case C-140/07, Hecht-Pharma GmbH v. Staatliches Gewerbeaufsichtsamt Luneburg, ECLI:EU:C:2009:5 (classification “by function” requires a case-by-case assessment of pharmacological, immunological or metabolic properties). See also Directive 2001/83, supra note 2, art. 2(2) (in cases of doubt, the medicinal-products regime prevails).</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a> Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on Nutrition and Health Claims Made on Foods, arts. 10, 13, 14, 2006 O.J. (L 404) 9 [hereinafter Health Claims Regulation]. The EU Register of nutrition and health claims is maintained by the European Commission.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a> Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 Concerning Unfair Business-to-Consumer Commercial Practices in the Internal Market, 2005 O.J. (L 149) 22 [hereinafter UCPD].</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a> Directive (EU) 2024/825 of the European Parliament and of the Council of 28 February 2024 Amending Directives 2005/29/EC and 2011/83/EU as Regards Empowering Consumers for the Green Transition, OJ L, 2024/825, 6.3.2024 [hereinafter ECGT Directive]. Member States were required to transpose the Directive by 27 March 2026; its provisions apply from 27 September 2026. The separate Green Claims Directive proposal, which would have introduced ex ante verification of explicit environmental claims, was withdrawn by the Commission in 2025 and is not discussed here.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a> Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 Laying Down Harmonised Rules on Artificial Intelligence, OJ L, 2024/1689, 12.7.2024 [hereinafter AI Act].</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a> AI Act, supra note 12, art. 6(1) &amp; Annex I, § A (listing the MDR and Regulation (EU) 2017/746 on in vitro diagnostic medical devices). The Annex I route applies where the AI system is a product, or a safety component of a product, that is itself subject to third-party conformity assessment under the listed Union harmonisation legislation.</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a> AI Act, supra note 12, arts. 9–15, 17, 43, 72.</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a> Regulation (EU) 2026/1744 of the European Parliament and of the Council Amending Regulation (EU) 2024/1689 as Regards the Simplification of Certain Obligations (“Digital Omnibus on AI”), OJ L, 2026/1744, 24.7.2026 (in force 27 July 2026). The Regulation defers the high-risk obligations for stand-alone (Annex III) systems to 2 December 2027 and for AI embedded in products covered by Annex I, including medical devices, to 2 August 2028; the Article 50 transparency obligations continue to apply from 2 August 2026.</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a> Eur. Medicines Agency, Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle, EMA/CHMP/CVMP/83833/2023 (adopted Sept. 2024).</p>



<p><a href="#_ftnref17" id="_ftn17">[17]</a> Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data, arts. 9(2)(j), 89, 2016 O.J. (L 119) 1 [hereinafter GDPR].</p>



<p><a href="#_ftnref18" id="_ftn18">[18]</a> Regulation (EU) 2025/327 of the European Parliament and of the Council of 11 February 2025 on the European Health Data Space, OJ L, 2025/327, 5.3.2025 [hereinafter EHDS Regulation]. The Regulation entered into force on 26 March 2025 and applies in stages: most provisions from 26 March 2027, and the core secondary-use chapter from 26 March 2029 (2031 for certain data categories). See id. art. 105.</p>



<p><a href="#_ftnref19" id="_ftn19">[19]</a> EHDS Regulation, supra note 18, arts. 50–54 (secure processing environments; permitted and prohibited purposes of secondary use).</p>



<p><a href="#_ftnref20" id="_ftn20">[20]</a> Directive 2001/83, supra note 2, art. 87(2) (all parts of advertising must comply with the particulars listed in the summary of product characteristics), arts. 40–53 (manufacturing authorisation and good manufacturing practice) and art. 87(1) (prohibition of advertising of medicinal products without a marketing authorisation).</p>



<p><a href="#_ftnref21" id="_ftn21">[21]</a> MDR, supra note 7, art. 7.</p>



<p><a href="#_ftnref22" id="_ftn22">[22]</a> Commission Decision (EU) 2025/2371 of 26 November 2025 (declaring the first four EUDAMED modules functional), OJ L, 2025/2371, 27.11.2025; Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024, OJ L, 2024/1860, 9.7.2024 (gradual roll-out of EUDAMED). The four modules (actor registration, UDI/device registration, notified bodies and certificates, market surveillance) are mandatory from 28 May 2026; legacy devices remaining on the market must be registered by 28 November 2026. The vigilance and clinical-investigation modules are not yet mandatory, and serious incidents continue to be reported to national competent authorities.</p>



<p><a href="#_ftnref23" id="_ftn23">[23]</a> Cosmetics Regulation, supra note 6, arts. 11, 13, 20; Commission Regulation (EU) No 655/2013 of 10 July 2013 Laying Down Common Criteria for the Justification of Claims Used in Relation to Cosmetic Products, Annex, 2013 O.J. (L 190) 31.</p>



<p><a href="#_ftnref24" id="_ftn24">[24]</a> Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 Laying Down the General Principles and Requirements of Food Law, 2002 O.J. (L 31) 1.</p>



<p><a href="#_ftnref25" id="_ftn25">[25]</a> Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 Authorising the Placing on the Market of Nicotinamide Riboside Chloride as a Novel Food, 2020 O.J. (L 7) 6.</p>



<p><a id="_ftn26" href="#_ftnref26">[26]</a> EFSA Panel on Nutrition, Novel Foods and Food Allergens, Safety of Beta-Nicotinamide Mononucleotide (β-NMN) Pursuant to Regulation (EU) 2015/2283 and the Bioavailability of Nicotinamide from This Source in the Context of Directive 2002/46/EC, 24 EFSA J. e10007 (2026) (opinion adopted 4 March 2026, published 11 May 2026). Authorisation requires a Commission implementing act amending the Union list established by Commission Implementing Regulation (EU) 2017/2470; at the time of writing no such act has been published, and any authorisation granted on the basis of proprietary data will initially benefit only the applicant. See Novel Food Regulation, supra note 5, arts. 12, 26.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective-2/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 15 Sep 2026 19:35:31 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[EU Regulatory Law]]></category>
		<category><![CDATA[European Health Data Space]]></category>
		<category><![CDATA[Food Supplements]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[Health Claims]]></category>
		<category><![CDATA[health tech]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Longevity Industry]]></category>
		<category><![CDATA[Longevity Washing]]></category>
		<category><![CDATA[Medical Devices Regulation]]></category>
		<category><![CDATA[Novel Foods]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8913</guid>

					<description><![CDATA[<p>Publication date: September 15, 2026 ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL I. Introduction The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color"><strong>Publication date: September 15, 2026</strong></mark></p>



<figure class="wp-block-video"><video controls src="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4"></video></figure>



<p class="has-luminous-vivid-amber-background-color has-background has-large-font-size">ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL</p>



<span id="more-8913"></span>



<p class="has-medium-font-size">I. Introduction</p>



<p>The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.<a href="#_ftn1" id="_ftnref1">[1]</a> Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.</p>



<p>The gap between an enormous market and a non-existent legal definition is precisely where legal risk accumulates. Where there is no definition, there is classification risk, claims risk, and enforcement risk. There is also a phenomenon that this article, borrowing from the vocabulary of environmental marketing, calls “longevity washing.”</p>



<p>This article examines the longevity industry through the lens of EU regulatory law. The EU framework governs a market of some 450 million consumers and, because it is horizontal, sector-specific, and increasingly enforcement-oriented, it offers a useful point of comparison for practitioners in the United States, Asia, and Latin America. Part II explains why “longevity” is not a legal category and introduces the borderline-product problem that follows from that fact. Part III develops the concept of longevity washing and its consumer-facing, unfair-commercial-practice, and investor-facing dimensions. Part IV addresses the regulation of artificial intelligence in longevity research and diagnostics, including the revised timeline of the AI Act, the position of the European Medicines Agency on AI in the medicinal-product lifecycle, and the data-protection architecture formed by the GDPR and the European Health Data Space. Part V maps the sectoral “hot spots” across pharmaceuticals, medical devices, cosmetics, and food supplements. Part VI draws conclusions for practitioners.</p>



<h3 class="wp-block-heading">II. “Longevity” in the Eyes of the Law: The Borderline-Product Problem</h3>



<p>In EU regulatory law, aging is not a disease. The European Medicines Agency has never approved a medicinal product with “aging” as a therapeutic indication, and under Directive 2001/83/EC a medicinal product is defined by reference to the treatment or prevention of disease or the restoration, correction, or modification of physiological functions.<a href="#_ftn2" id="_ftnref2">[2]</a> The position in the United States is comparable. The long-running debate around the Targeting Aging with Metformin (TAME) trial illustrates the point: its designers had to negotiate a trial protocol with the Food and Drug Administration that targets aging indirectly, through a composite of age-related diseases, precisely because “aging” itself is not an approvable indication.<a href="#_ftn3" id="_ftnref3">[3]</a></p>



<p>The consequence is profound. A company cannot lawfully market a product “to treat aging.” The entire longevity industry therefore operates in the space of indirect claims: “supports healthy aging,” “promotes cellular health,” “extends healthspan.” Each of those phrases pushes the product toward one of several very different regulatory regimes.</p>



<p>This is the borderline-product problem, and it is the single most important legal concept in the sector. The same molecule – an NAD precursor, for example – may be: a medicinal product, if it is presented as treating or preventing disease or exerts a significant pharmacological, immunological, or metabolic effect; a food supplement under Directive 2002/46/EC;<a href="#_ftn4" id="_ftnref4">[4]</a> a novel food requiring pre-market authorisation under Regulation (EU) 2015/2283;<a href="#_ftn5" id="_ftnref5">[5]</a> a cosmetic under Regulation (EC) No 1223/2009, if applied to the skin with a claim limited to appearance;<a href="#_ftn6" id="_ftnref6">[6]</a> or a medical device. The last category is broader than it may appear: since the Medical Device Regulation (MDR) came into application, products listed in its Annex XVI – dermal fillers, certain energy-based aesthetic equipment – are regulated as devices even where they have no medical purpose at all.<a href="#_ftn7" id="_ftnref7">[7]</a></p>



<p>Classification does not follow the label a company chooses. It follows presentation, composition, and route of administration. The Court of Justice of the European Union has held for four decades that a product is a medicinal product “by presentation” where it is described or recommended as having properties for treating or preventing disease, irrespective of whether it actually has those properties; and that classification “by function” turns on a case-by-case scientific assessment of the product’s actual pharmacological, immunological, or metabolic action, not on the manufacturer’s intention.<a href="#_ftn8" id="_ftnref8">[8]</a> Marketing language alone can therefore reclassify a product and, with it, the entire compliance burden: marketing authorisation, good manufacturing practice, pharmacovigilance, and advertising restrictions.</p>



<p>When a client says “we are a longevity company,” the first question counsel should ask is: <em>which regime are you actually in?</em> “Longevity” is a marketing word. The law knows only medicines, devices, foods, and cosmetics.</p>



<h3 class="wp-block-heading">III. Longevity Washing: When the Claim Outruns the Science</h3>



<p>Greenwashing – claiming environmental virtue one does not have – is a familiar concept. Longevity washing is its younger sibling: labelling a product, a clinic, a research programme, or an entire company as “longevity-focused” when the science, the indication, or the business model does not support that description. The practice matters legally for three reasons.</p>



<h2 class="wp-block-heading"><em>A. Consumer-Facing Claims</em></h2>



<p>Under the Health Claims Regulation, any health claim made on a food – and food supplements are foods – must be specifically authorised and listed in the EU register.<a href="#_ftn9" id="_ftnref9">[9]</a> Claims such as “slows aging,” “supports cellular repair,” or “extends lifespan” are not authorised health claims. National authorities in the EU and the United Kingdom have treated phrases such as “cellular repair” and even “healthy aging” as impermissible where they imply a physiological mechanism or a reduction of disease risk. A substantial part of the longevity supplement market is thus operating with claims that would not survive enforcement scrutiny.</p>



<h2 class="wp-block-heading"><em>B. Unfair Commercial Practices and the Greenwashing Template</em></h2>



<p>The second layer is the general prohibition of misleading commercial practices under the Unfair Commercial Practices Directive (UCPD).<a href="#_ftn10" id="_ftnref10">[10]</a> Here the EU has recently built an entire enforcement architecture against greenwashing that repays close study by anyone advising on health claims. The Empowering Consumers for the Green Transition Directive amends the UCPD to prohibit generic environmental claims – “eco-friendly,” “climate-neutral” – unless the trader can demonstrate recognised excellent environmental performance, and it adds a series of specific greenwashing practices to the UCPD’s blacklist. Its provisions apply across the Union from 27 September 2026.<a href="#_ftn11" id="_ftnref11">[11]</a></p>



<p>The Directive should be read as a template. If “climate-neutral” now requires substantiation, it is a very short doctrinal step for regulators and courts to demand the same of “clinically proven to slow biological aging.” The methodology of anti-greenwashing enforcement – generic claim, absence of substantiation, misleading omission – maps directly onto longevity claims. The UCPD’s general clauses on misleading actions and omissions already provide the legal basis; what the green-claims reform supplies is a worked example of how those clauses can be operationalised against vague virtue-signalling.</p>



<h2 class="wp-block-heading"><em>C. Investor-Facing Washing</em></h2>



<p>The third dimension is of particular relevance to transactional lawyers. Start-ups increasingly brand themselves as “longevity biotech” because that is where the capital is, even when the underlying asset is a conventional dermatology product or a wellness application. For investors, this creates due-diligence risk: is the “longevity platform” in fact a regulated medicinal pipeline, with all the timeline and cost that implies, or a supplement business one enforcement letter away from relabelling? Misclassification discovered after investment is a valuation event. For the company, aggressive longevity framing in fundraising materials can generate liability under securities and misrepresentation rules in multiple jurisdictions. In due diligence on a longevity start-up, the regulatory classification memorandum is not an annex to the deal; it <em>is</em> the deal.</p>



<h3 class="wp-block-heading">IV. Artificial Intelligence in Longevity Research and Diagnostics</h3>



<p>The longevity field is arguably the most AI-dependent sector in the life sciences, for a simple reason: aging is not one target but thousands of interacting biological processes. A geroprotective drug cannot be designed the way an antibiotic is designed. The entire aging phenotype must be modelled, and that means machine learning on large multi-omic datasets. AI is not an add-on in longevity; it is the core methodology. That raises three distinct regulatory questions under EU law.</p>



<h2 class="wp-block-heading"><em>A. The AI Act</em></h2>



<p>Regulation (EU) 2024/1689, the AI Act, is the most comprehensive horizontal AI regulation in force anywhere and applies to almost every AI system used in the longevity value chain.<a href="#_ftn12" id="_ftnref12">[12]</a> It adopts a risk-based structure – prohibited practices, high-risk systems, transparency obligations, and minimal-risk systems – and the critical category for this sector is high-risk. An AI system that is itself a medical device, or a safety component of one, under the MDR or the In Vitro Diagnostic Regulation, and that is subject to third-party conformity assessment under those instruments, is high-risk under Article 6(1) and Annex I of the AI Act.<a href="#_ftn13" id="_ftnref13">[13]</a> This captures, for example, an AI tool that estimates a patient’s “biological age” from a blood panel and uses that estimate to guide a clinical intervention; an AI-driven diagnostic that predicts age-related disease risk; and the software layer of many longevity-clinic platforms once it makes a diagnostic or prognostic claim.</p>



<p>High-risk status is not a prohibition; it is a compliance regime. It requires a risk-management system, data governance with representative and bias-tested training data, technical documentation, logging, human oversight, transparency to deployers, accuracy, robustness and cybersecurity, a conformity assessment, and post-market monitoring.<a href="#_ftn14" id="_ftnref14">[14]</a> For most longevity start-ups this is a wholly new compliance layer on top of MDR conformity assessment, and the two must be coordinated.</p>



<p>The timeline has recently changed, and practitioners should update their advice accordingly. The original AI Act applied the high-risk obligations from 2 August 2026 for stand-alone systems listed in Annex III and from 2 August 2027 for AI embedded in products covered by Annex I, including medical devices. The Digital Omnibus on AI, adopted as Regulation (EU) 2026/1744 and in force since 27 July 2026, defers those dates to 2 December 2027 and 2 August 2028 respectively.<a href="#_ftn15" id="_ftnref15">[15]</a> The deferral does not lighten the substantive regime; the prohibitions in Article 5, the obligations of providers of general-purpose AI models, and the transparency obligations of Article 50 (which apply from 2 August 2026) are unaffected. For longevity companies whose AI is a medical device, the practical effect is a compliance window of roughly two years, during which harmonised standards and notified-body capacity are expected to mature. The window is an opportunity to design AI Act compliance into the MDR technical file from the outset rather than to defer the exercise.</p>



<h2 class="wp-block-heading"><em>B. AI in Drug Discovery and the European Medicines Agency</em></h2>



<p>The position for drug discovery is more nuanced. An AI model used purely internally to identify candidate molecules – the classic “AI for drug discovery” use case that dominates longevity-biotech pitch decks – is generally not, in itself, a high-risk AI system under the AI Act, because it does not make or materially influence decisions about individual patients. The regulatory question shifts instead to the European Medicines Agency. The EMA’s Reflection Paper on the use of AI in the medicinal product lifecycle sets out the Agency’s expectations from discovery through pharmacovigilance.<a href="#_ftn16" id="_ftnref16">[16]</a> Its core message is that the burden of proof rests on the sponsor to demonstrate that the AI model is fit for its regulatory purpose. That entails documented data provenance, model validation, a degree of explainability appropriate to the stage of development, and lifecycle management of the model itself.</p>



<p>If a longevity company tells its investors that “our AI discovered this molecule,” the regulator will eventually ask to see the model, the training data, and the validation. Vague AI claims in fundraising materials do not survive regulatory scrutiny and, increasingly, do not survive investor due diligence either.</p>



<h2 class="wp-block-heading"><em>C. Data: The GDPR and the European Health Data Space</em></h2>



<p>The third question concerns data, and it is here that longevity becomes uniquely difficult. Aging research is inherently longitudinal and multi-omic: genomic, epigenetic, and proteomic data, wearable data, and medical records, ideally across decades. Under the General Data Protection Regulation this is special-category data – health, genetic, and biometric data – and the available lawful bases are narrow.<a href="#_ftn17" id="_ftnref17">[17]</a> The scientific-research provisions of Article 9(2)(j) and Article 89 assist, but they are implemented differently in each Member State, which produces real fragmentation for pan-European longevity cohorts.</p>



<p>The European Health Data Space Regulation adds a second layer.<a id="_ftnref18" href="#_ftn18">[18]</a> It creates, for the first time, a mandatory EU-wide framework for the secondary use of electronic health data, administered by health-data-access bodies in each Member State. For longevity research the EHDS is potentially transformative, because it opens access to population-scale health data for research purposes. It also imposes strict conditions: purpose limitation, processing only within secure processing environments, a prohibition on re-identification, and specific prohibitions on using the data for advertising or marketing, for decisions detrimental to individuals such as insurance or employment decisions, or for developing products harmful to health.<a id="_ftnref19" href="#_ftn19">[19]</a> The secondary-use chapter applies from March 2029 for most data categories, but the lead time is short in the context of longitudinal cohorts. Longevity companies that intend to monetise health data – and many do – should be mapping their data flows against the EHDS regime now.</p>



<h3 class="wp-block-heading">V. Sector-by-Sector Regulatory Hot Spots</h3>



<p>Four sectoral silos together make up the longevity industry, and the same start-up frequently straddles two or three of them without realising it. In each silo, specific “hot spots” – advertising, manufacturing standards, registration, and market withdrawal – recur in practice.</p>



<h2 class="wp-block-heading"><em>A. Pharmaceuticals</em></h2>



<p>True longevity drugs – rapamycin analogues, senolytics, geroprotectors – sit squarely within Directive 2001/83/EC and its implementing rules, and will continue to do so under the new pharmaceutical package once it applies. Three practical hot spots stand out. First, off-label prescribing of rapamycin and metformin for longevity indications is widespread in private clinics across Europe. Off-label prescribing as such is a matter of clinical freedom, but off-label <em>promotion</em> by or on behalf of the marketing-authorisation holder is prohibited: advertising must conform to the summary of product characteristics, and advertising of unauthorised products or indications is not permitted.<a href="#_ftn20" id="_ftnref20">[20]</a> Longevity clinics are increasingly the vehicle through which promotional messaging reaches patients, and enforcement authorities have begun to take notice. Second, good manufacturing practice: anything presented as a medicine must be manufactured under an EU manufacturing authorisation and EU GMP, with qualified persons and full traceability; compounding pharmacies producing “longevity peptides” have become a significant enforcement target. Third, unlicensed importation: a large part of the longevity-peptide market operates through personal importation and grey channels, and customs enforcement across the EU has visibly tightened.</p>



<h2 class="wp-block-heading"><em>B. Medical Devices</em></h2>



<p>The MDR has fundamentally reshaped this space. Aesthetic devices – dermal fillers, energy-based devices used in longevity clinics, at-home devices marketed for “cellular rejuvenation” – are caught by Annex XVI even without a medical purpose. Three hot spots follow. Classification: many longevity wearables and applications become software as a medical device once they make a diagnostic or prognostic claim. Advertising: Article 7 of the MDR prohibits misleading claims and specifically prohibits ascribing to a device functions and properties it does not have, which operates in practice as a codified anti-washing rule for devices.<a href="#_ftn21" id="_ftnref21">[21]</a> Registration and vigilance: the first four modules of the EUDAMED database – actor registration, UDI/device registration, notified bodies and certificates, and market surveillance – have been mandatory since 28 May 2026, with legacy devices to be registered by 28 November 2026; the vigilance module is not yet mandatory, so serious incidents and field safety corrective actions continue to be reported to national competent authorities.<a href="#_ftn22" id="_ftnref22">[22]</a> Market withdrawals happen: a device sold as a “cellular biomarker analyser” without valid clinical evidence can be removed from the market by any national competent authority, and the MDR’s market-surveillance coordination means that one withdrawal can cascade across the Union.</p>



<h2 class="wp-block-heading"><em>C. Cosmetics and Aesthetic Products</em></h2>



<p>The Cosmetics Regulation governs anti-aging creams, serums, and topical actives. Two hot spots dominate. The first is the Product Information File: the responsible person must hold a complete file including a safety assessment and substantiation of every claim. The second is the Claims Regulation, Commission Regulation (EU) No 655/2013, with its six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making.<a href="#_ftn23" id="_ftnref23">[23]</a> A claim such as “reverses skin aging at the cellular level” fails the evidential-support criterion unless a robust dossier stands behind it. Enforcement is largely national, but the Cosmetic Products Notification Portal is EU-wide, and non-compliant products are routinely notified through the Safety Gate rapid-alert system.</p>



<h2 class="wp-block-heading"><em>D. Food Supplements and Novel Foods</em></h2>



<p>It is in the food and supplement space that the longevity industry is most creative and most exposed. Directive 2002/46/EC governs vitamins and minerals in supplements; everything else falls under the general food law of Regulation (EC) No 178/2002<a href="#_ftn24" id="_ftnref24">[24]</a> and, critically, the Novel Food Regulation. Nicotinamide mononucleotide (NMN), one of the most heavily marketed longevity molecules, is the paradigmatic case. NMN is treated as a novel food in the EU, which means it cannot lawfully be placed on the market as a supplement without pre-market authorisation by the Commission following an EFSA safety assessment. Nicotinamide riboside received such an authorisation in 2020.<a href="#_ftn25" id="_ftnref25">[25]</a> NMN has not – although the picture is now moving. In March 2026 EFSA’s NDA Panel adopted a positive opinion on the safety of β-NMN in food supplements at up to 300 mg per day for adults, and the opinion was published in May 2026.<a href="#_ftn26" id="_ftnref26">[26]</a> An EFSA opinion is a scientific assessment, not an authorisation; the Commission must still adopt an implementing act adding NMN to the Union list, and where the applicant has requested data protection the authorisation will initially be proprietary to that applicant’s specification. Until that act is adopted, NMN products on the shelves of European longevity clinics remain unauthorised novel foods. That is not a grey area; it is a non-compliant market operating in plain sight, and it is the kind of enforcement pipeline that eventually produces high-profile withdrawal actions. Once the Health Claims Regulation is added to the picture, the conclusion is unavoidable: the food and supplement leg of the longevity industry is the most legally exposed part of the entire sector.</p>



<h1 class="wp-block-heading">VI. Conclusions</h1>



<p>The longevity industry is a genuine scientific and commercial phenomenon, and much of the underlying research is serious. But lawyers advising companies, investors, clinicians, and, increasingly, regulators in this space must see it clearly: “longevity” is not a legal category. It is a marketing frame layered on top of four very different regulatory regimes. Three practical conclusions follow for anyone whose product touches European consumers.</p>



<p>First, always begin with classification. The word “longevity” conveys nothing about the applicable regime. Ask what the product is, how it is presented, and what it does, and let the regulatory regime follow from those answers.</p>



<p>Second, treat longevity claims the way green claims are now treated. The direction of enforcement is unmistakable. The Empowering Consumers for the Green Transition Directive, applicable from 27 September 2026, gives regulators a sharpened toolkit that will, sooner or later, be pointed at health and wellness claims. Substantiation is no longer optional.</p>



<p>Third, integrate AI Act compliance with sectoral compliance from the outset. For any longevity venture using AI in diagnostics or patient-facing decision support, the AI Act, the MDR, and the GDPR, soon joined by the European Health Data Space, form a single interlocking compliance architecture. The deferral of the AI Act’s high-risk obligations to 2027 and 2028 is a design window, not a reprieve. Retrofitting is expensive; designing for compliance is not.</p>



<p>The longevity industry will keep growing, and regulators will keep catching up. The lawyers who understand both the science and the sectoral map will be the ones clients call first.</p>



<hr class="wp-block-separator has-alpha-channel-opacity"/>



<p><a href="#_ftnref1" id="_ftn1">[1]</a> Longevity economy estimates vary widely by definition; see, e.g., the periodic longevity-market reports of Bank of America Global Research and McKinsey Health Institute. The figure is offered here as an order of magnitude, not a precise valuation.</p>



<p><a href="#_ftnref2" id="_ftn2">[2]</a> Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, art. 1(2), 2001 O.J. (L 311) 67 [hereinafter Directive 2001/83]. At the time of writing, the new EU pharmaceutical package (a new directive on the Union code for medicinal products for human use and a new regulation on Union authorisation procedures) has been politically agreed and is in the final stage of formal adoption; the substantive rules discussed here are carried over into the new framework, which will apply after a transitional period of approximately two years from entry into force.</p>



<p><a href="#_ftnref3" id="_ftn3">[3]</a> See Nir Barzilai et al., Metformin as a Tool to Target Aging, 23 Cell Metabolism 1060 (2016) (describing the design of the Targeting Aging with Metformin (TAME) trial around a composite of age-related diseases).</p>



<p><a href="#_ftnref4" id="_ftn4">[4]</a> Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the Approximation of the Laws of the Member States Relating to Food Supplements, 2002 O.J. (L 183) 51.</p>



<p><a href="#_ftnref5" id="_ftn5">[5]</a> Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on Novel Foods, 2015 O.J. (L 327) 1 [hereinafter Novel Food Regulation].</p>



<p><a href="#_ftnref6" id="_ftn6">[6]</a> Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on Cosmetic Products, 2009 O.J. (L 342) 59 [hereinafter Cosmetics Regulation].</p>



<p><a href="#_ftnref7" id="_ftn7">[7]</a> Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Annex XVI, 2017 O.J. (L 117) 1 [hereinafter MDR]; Commission Implementing Regulation (EU) 2022/2346 of 1 December 2022 Laying Down Common Specifications for the Groups of Products Without an Intended Medical Purpose Listed in Annex XVI, 2022 O.J. (L 311) 60.</p>



<p><a href="#_ftnref8" id="_ftn8">[8]</a> Case 227/82, Van Bennekom, ECLI:EU:C:1983:354 (establishing that a product is a medicinal product “by presentation” where it is described or recommended as having therapeutic or prophylactic properties, irrespective of its actual efficacy); Case C-319/05, Comm’n v. Germany, ECLI:EU:C:2007:678 (garlic capsules); Case C-140/07, Hecht-Pharma GmbH v. Staatliches Gewerbeaufsichtsamt Luneburg, ECLI:EU:C:2009:5 (classification “by function” requires a case-by-case assessment of pharmacological, immunological or metabolic properties). See also Directive 2001/83, supra note 2, art. 2(2) (in cases of doubt, the medicinal-products regime prevails).</p>



<p><a href="#_ftnref9" id="_ftn9">[9]</a> Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on Nutrition and Health Claims Made on Foods, arts. 10, 13, 14, 2006 O.J. (L 404) 9 [hereinafter Health Claims Regulation]. The EU Register of nutrition and health claims is maintained by the European Commission.</p>



<p><a href="#_ftnref10" id="_ftn10">[10]</a> Directive 2005/29/EC of the European Parliament and of the Council of 11 May 2005 Concerning Unfair Business-to-Consumer Commercial Practices in the Internal Market, 2005 O.J. (L 149) 22 [hereinafter UCPD].</p>



<p><a href="#_ftnref11" id="_ftn11">[11]</a> Directive (EU) 2024/825 of the European Parliament and of the Council of 28 February 2024 Amending Directives 2005/29/EC and 2011/83/EU as Regards Empowering Consumers for the Green Transition, OJ L, 2024/825, 6.3.2024 [hereinafter ECGT Directive]. Member States were required to transpose the Directive by 27 March 2026; its provisions apply from 27 September 2026. The separate Green Claims Directive proposal, which would have introduced ex ante verification of explicit environmental claims, was withdrawn by the Commission in 2025 and is not discussed here.</p>



<p><a href="#_ftnref12" id="_ftn12">[12]</a> Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 Laying Down Harmonised Rules on Artificial Intelligence, OJ L, 2024/1689, 12.7.2024 [hereinafter AI Act].</p>



<p><a href="#_ftnref13" id="_ftn13">[13]</a> AI Act, supra note 12, art. 6(1) &amp; Annex I, § A (listing the MDR and Regulation (EU) 2017/746 on in vitro diagnostic medical devices). The Annex I route applies where the AI system is a product, or a safety component of a product, that is itself subject to third-party conformity assessment under the listed Union harmonisation legislation.</p>



<p><a href="#_ftnref14" id="_ftn14">[14]</a> AI Act, supra note 12, arts. 9–15, 17, 43, 72.</p>



<p><a href="#_ftnref15" id="_ftn15">[15]</a> Regulation (EU) 2026/1744 of the European Parliament and of the Council Amending Regulation (EU) 2024/1689 as Regards the Simplification of Certain Obligations (“Digital Omnibus on AI”), OJ L, 2026/1744, 24.7.2026 (in force 27 July 2026). The Regulation defers the high-risk obligations for stand-alone (Annex III) systems to 2 December 2027 and for AI embedded in products covered by Annex I, including medical devices, to 2 August 2028; the Article 50 transparency obligations continue to apply from 2 August 2026.</p>



<p><a href="#_ftnref16" id="_ftn16">[16]</a> Eur. Medicines Agency, Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle, EMA/CHMP/CVMP/83833/2023 (adopted Sept. 2024).</p>



<p><a href="#_ftnref17" id="_ftn17">[17]</a> Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data, arts. 9(2)(j), 89, 2016 O.J. (L 119) 1 [hereinafter GDPR].</p>



<p><a href="#_ftnref18" id="_ftn18">[18]</a> Regulation (EU) 2025/327 of the European Parliament and of the Council of 11 February 2025 on the European Health Data Space, OJ L, 2025/327, 5.3.2025 [hereinafter EHDS Regulation]. The Regulation entered into force on 26 March 2025 and applies in stages: most provisions from 26 March 2027, and the core secondary-use chapter from 26 March 2029 (2031 for certain data categories). See id. art. 105.</p>



<p><a href="#_ftnref19" id="_ftn19">[19]</a> EHDS Regulation, supra note 18, arts. 50–54 (secure processing environments; permitted and prohibited purposes of secondary use).</p>



<p><a href="#_ftnref20" id="_ftn20">[20]</a> Directive 2001/83, supra note 2, art. 87(2) (all parts of advertising must comply with the particulars listed in the summary of product characteristics), arts. 40–53 (manufacturing authorisation and good manufacturing practice) and art. 87(1) (prohibition of advertising of medicinal products without a marketing authorisation).</p>



<p><a href="#_ftnref21" id="_ftn21">[21]</a> MDR, supra note 7, art. 7.</p>



<p><a href="#_ftnref22" id="_ftn22">[22]</a> Commission Decision (EU) 2025/2371 of 26 November 2025 (declaring the first four EUDAMED modules functional), OJ L, 2025/2371, 27.11.2025; Regulation (EU) 2024/1860 of the European Parliament and of the Council of 13 June 2024, OJ L, 2024/1860, 9.7.2024 (gradual roll-out of EUDAMED). The four modules (actor registration, UDI/device registration, notified bodies and certificates, market surveillance) are mandatory from 28 May 2026; legacy devices remaining on the market must be registered by 28 November 2026. The vigilance and clinical-investigation modules are not yet mandatory, and serious incidents continue to be reported to national competent authorities.</p>



<p><a href="#_ftnref23" id="_ftn23">[23]</a> Cosmetics Regulation, supra note 6, arts. 11, 13, 20; Commission Regulation (EU) No 655/2013 of 10 July 2013 Laying Down Common Criteria for the Justification of Claims Used in Relation to Cosmetic Products, Annex, 2013 O.J. (L 190) 31.</p>



<p><a href="#_ftnref24" id="_ftn24">[24]</a> Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 Laying Down the General Principles and Requirements of Food Law, 2002 O.J. (L 31) 1.</p>



<p><a href="#_ftnref25" id="_ftn25">[25]</a> Commission Implementing Regulation (EU) 2020/16 of 10 January 2020 Authorising the Placing on the Market of Nicotinamide Riboside Chloride as a Novel Food, 2020 O.J. (L 7) 6.</p>



<p><a id="_ftn26" href="#_ftnref26">[26]</a> EFSA Panel on Nutrition, Novel Foods and Food Allergens, Safety of Beta-Nicotinamide Mononucleotide (β-NMN) Pursuant to Regulation (EU) 2015/2283 and the Bioavailability of Nicotinamide from This Source in the Context of Directive 2002/46/EC, 24 EFSA J. e10007 (2026) (opinion adopted 4 March 2026, published 11 May 2026). Authorisation requires a Commission implementing act amending the Union list established by Commission Implementing Regulation (EU) 2017/2470; at the time of writing no such act has been published, and any authorisation granted on the basis of proprietary data will initially benefit only the applicant. See Novel Food Regulation, supra note 5, arts. 12, 26.</p>
<p> </p>



<p>#LongevityIndustry #LongevityWashing #EURegulatoryLaw #ArtificialIntelligence #AIAct #HealthcareLaw #LifeSciencesLaw #HealthTech #MedicalDevices #PharmaceuticalLaw #GDPR #EuropeanHealthDataSpace #EUlaw #HealthClaims #NovelFoods</p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/">Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/longevity-washing-ai-and-the-regulatory-fault-lines-of-the-longevity-industry-a-european-perspective/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		<enclosure url="https://www.kg-legal.eu/wp-content/uploads/2026/09/ABA_Call_Longevity_Presentation-wrzesien.mp4" length="12991488" type="video/mp4" />

			</item>
		<item>
		<title>A Major Milestone for KG Legal&#8217;s Data, AI &#038; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</title>
		<link>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/</link>
					<comments>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 19:32:01 +0000</pubDate>
				<category><![CDATA[KG LEGAL NEWS]]></category>
		<category><![CDATA[AI Act]]></category>
		<category><![CDATA[AI Compliance]]></category>
		<category><![CDATA[AI Regulation]]></category>
		<category><![CDATA[Artificial intelligence]]></category>
		<category><![CDATA[CEE]]></category>
		<category><![CDATA[Corporate Counsel]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Cross Border Legal Services]]></category>
		<category><![CDATA[Cyber Compliance]]></category>
		<category><![CDATA[Cyber Law]]></category>
		<category><![CDATA[Data Governance]]></category>
		<category><![CDATA[Data Privacy]]></category>
		<category><![CDATA[data protection]]></category>
		<category><![CDATA[DataGuidance]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Digital Economy]]></category>
		<category><![CDATA[Digital Law]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[Emerging Technologies]]></category>
		<category><![CDATA[EU Law]]></category>
		<category><![CDATA[European Law]]></category>
		<category><![CDATA[Foreign Investors]]></category>
		<category><![CDATA[gdpr]]></category>
		<category><![CDATA[GDPR Compliance]]></category>
		<category><![CDATA[GDPR Poland]]></category>
		<category><![CDATA[General Counsel]]></category>
		<category><![CDATA[Global Law]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[Healthcare Regulation]]></category>
		<category><![CDATA[In House Counsel]]></category>
		<category><![CDATA[International Law Firm]]></category>
		<category><![CDATA[International Legal Services]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[kglegal]]></category>
		<category><![CDATA[kiełtyka gładkowski]]></category>
		<category><![CDATA[Law Firm Poland]]></category>
		<category><![CDATA[Legal Innovation]]></category>
		<category><![CDATA[Legal Tech]]></category>
		<category><![CDATA[Legal Thought Leadership]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[NIS2]]></category>
		<category><![CDATA[OneTrust]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Polish Law Firm]]></category>
		<category><![CDATA[Privacy Law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Technology Law]]></category>
		<category><![CDATA[Technology Transactions]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8822</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 We are delighted to share an important milestone in the continued development of KG Legal&#8217;s Data, AI &#38; Cybersecurity Desk. It has been a great honour to serve as the exclusive expert contributors for Poland to the OneTrust DataGuidance Privacy Overview – Poland, one of the world&#8217;s leading professional legal [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>We are delighted to share an important milestone in the continued development of <strong>KG Legal&#8217;s Data, AI &amp; Cybersecurity Desk</strong>.</p>



<figure class="wp-block-image size-full"><img fetchpriority="high" decoding="async" width="1000" height="1000" src="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png" alt="" class="wp-image-8823" srcset="https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge.png 1000w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-300x300.png 300w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-150x150.png 150w, https://www.kg-legal.eu/wp-content/uploads/2026/07/DataGuidance-Contributor-Badge-768x768.png 768w" sizes="(max-width: 1000px) 100vw, 1000px" /></figure>



<p>It has been a great honour to serve as the <strong>exclusive expert contributors for Poland</strong> to the <strong>OneTrust DataGuidance Privacy Overview – Poland</strong>, one of the world&#8217;s leading professional legal compliance resources relied upon by in-house counsel, privacy professionals, compliance officers, multinational organisations and technology companies operating across multiple jurisdictions.</p>



<span id="more-8822"></span>



<p>Preparing this contribution was a long-term project that required several months of intensive legal analysis, research and editorial work. Our objective was not simply to describe the application of the GDPR in Poland. Instead, we sought to create a practical and comprehensive guide reflecting the significant transformation of the Polish regulatory landscape that has taken place in recent years as a result of new European legislation and its implementation into Polish law.</p>



<p>The publication therefore extends far beyond a traditional overview of Polish data protection law. It examines the interaction between privacy, digital regulation, cybersecurity and artificial intelligence, providing readers with practical guidance on the most important legal developments affecting organisations operating in Poland.</p>



<p>Our contribution discusses, among other things:</p>



<ul class="wp-block-list">
<li>the practical application of the GDPR within the Polish legal system;</li>



<li>the powers and regulatory practice of the Polish supervisory authority for personal data protection;</li>



<li>employee monitoring and workplace privacy;</li>



<li>cookies, consent mechanisms and online tracking technologies;</li>



<li>electronic communications and direct marketing requirements;</li>



<li>international data transfers;</li>



<li>personal data breaches and notification obligations;</li>



<li>practical compliance with Polish privacy legislation;</li>



<li>cybersecurity-related regulatory developments;</li>



<li>the growing interaction between data protection and artificial intelligence governance.</li>
</ul>



<p>A particularly important aspect of this work was addressing the rapidly evolving legislative environment. During the last few years, Poland has experienced substantial regulatory changes resulting from the implementation of numerous European legal instruments and the entry into force of directly applicable EU regulations that significantly affect organisations processing personal data.</p>



<p>Accordingly, the publication takes into account the practical implications of the evolving European digital regulatory framework, including the interaction between the GDPR and newer legal instruments governing digital services, artificial intelligence, cybersecurity and data governance. The analysis also reflects the impact of the AI regulatory framework, developments concerning data governance and electronic communications, as well as the increasingly interconnected compliance obligations facing businesses operating in today&#8217;s digital economy.</p>



<p>Rather than presenting legislation in isolation, the publication adopts a practical, compliance-oriented perspective. It combines:</p>



<ul class="wp-block-list">
<li>the GDPR and Polish implementing legislation;</li>



<li>guidance issued by the European Data Protection Board (EDPB);</li>



<li>the jurisprudence of the Court of Justice of the European Union;</li>



<li>decisions and regulatory guidance published by the Polish Personal Data Protection Office (UODO);</li>



<li>recent Polish legislative developments and market practice.</li>
</ul>



<p>Our ambition was to create a resource that would assist both international and domestic organisations in navigating one of the fastest-changing areas of European regulation, where privacy law increasingly intersects with cybersecurity, AI governance, digital platforms, online communications and emerging technologies.</p>



<p>The contribution was prepared by <strong>Małgorzata Kiełtyka</strong> and <strong>Jakub Gładkowski</strong>, whose combined experience covers complex cross-border advisory work in data protection, artificial intelligence, life sciences, healthcare, technology law, cybersecurity, intellectual property and regulatory compliance.</p>



<p><a href="https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski" target="_blank" rel="noreferrer noopener">https://www.dataguidance.com/experts-directory/Jakub_G%C5%82adkowski</a></p>



<p><a href="https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka">https://www.dataguidance.com/experts-directory/Malgorzata_Kieltyka</a></p>



<p>For many years, Małgorzata Kiełtyka has advised international companies on GDPR compliance, healthcare regulation, AI governance, technology transactions and cross-border regulatory matters. Her practice combines strategic legal advice with practical implementation of compliance frameworks for multinational businesses operating in highly regulated sectors.</p>



<p>Jakub Gładkowski focuses on data protection, digital regulation, cybersecurity, intellectual property, IT law and emerging technologies. His practice includes advising innovative businesses on regulatory compliance, digital transformation projects and the implementation of European technology legislation affecting both public and private sector organisations.</p>



<p>Being entrusted with preparing Poland&#8217;s national contribution to OneTrust DataGuidance represents an important recognition of our team&#8217;s expertise and international standing. We are particularly proud that this publication reflects not only our experience in privacy law, but also our broader interdisciplinary approach, integrating data protection with AI regulation, cybersecurity, digital compliance and technology law.</p>



<p>We sincerely thank the editorial team at <strong>OneTrust DataGuidance</strong> for their confidence in our expertise and for the opportunity to contribute to a publication that supports legal and compliance professionals around the world.</p>



<p>For KG Legal, this publication marks another significant milestone in the continued growth of our <strong>Data, AI &amp; Cybersecurity Desk</strong> and reinforces our commitment to delivering practical, business-oriented legal advice at the intersection of privacy, technology and innovation.</p>
<p> </p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/">A Major Milestone for KG Legal&#8217;s Data, AI &amp; Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/kg-legal-news/a-major-milestone-for-kg-legals-data-ai-cybersecurity-practice-exclusive-poland-contribution-to-onetrust-dataguidance/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 18:09:37 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Administrative Law]]></category>
		<category><![CDATA[Advertising Law]]></category>
		<category><![CDATA[Compliance Risk]]></category>
		<category><![CDATA[CONSUMER PROTECTION]]></category>
		<category><![CDATA[Corporate Compliance]]></category>
		<category><![CDATA[Cross Border Business]]></category>
		<category><![CDATA[Digital Compliance]]></category>
		<category><![CDATA[Doing business in Poland]]></category>
		<category><![CDATA[EU Food Regulation]]></category>
		<category><![CDATA[eu regulation]]></category>
		<category><![CDATA[Food Law]]></category>
		<category><![CDATA[Food Safety]]></category>
		<category><![CDATA[GIS Poland]]></category>
		<category><![CDATA[Healthcare Law]]></category>
		<category><![CDATA[International Law Firms]]></category>
		<category><![CDATA[Invest in Poland]]></category>
		<category><![CDATA[Legal Services Poland]]></category>
		<category><![CDATA[Life Sciences Law]]></category>
		<category><![CDATA[Life Sciences Regulation]]></category>
		<category><![CDATA[Marketing Compliance]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Poland Law]]></category>
		<category><![CDATA[Polish law]]></category>
		<category><![CDATA[Regulatory Compliance]]></category>
		<category><![CDATA[Sanitary Regulation]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8807</guid>

					<description><![CDATA[<p>Publication date: July 07, 2026 The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: July 07, 2026</mark></strong></p>



<p>The Polish dietary supplements market is facing the most significant regulatory overhaul in years. The draft amendment to the Act on Food and Nutrition Safety and the Act on the State Sanitary Inspectorate introduces a series of far-reaching changes that will substantially alter the way supplements are notified, monitored, advertised, and supervised in Poland. While the reform does not formally introduce a pre-market authorization system, it undeniably strengthens the position of regulatory authorities and increases the compliance burden imposed on businesses operating in the sector.</p>



<span id="more-8807"></span>



<p id="ember2883">The amendment, expected to enter into force six months after publication, reflects both domestic concerns regarding the rapid expansion of the supplements market and the broader European trend toward stricter food safety oversight. For manufacturers, importers, distributors, and marketing agencies, the proposed changes may require a complete reassessment of internal procedures, legal risk management, and commercial strategy.</p>



<p id="ember2884">The reform arrives at a time when the Polish dietary supplements market continues to expand at an exceptional pace. Poland has become one of the largest supplement consumers in the European Union, both in terms of total market value and per capita spending. According to market estimates, the sector exceeded PLN 7 billion in value in 2024 and is expected to continue growing steadily over the coming years. The scale of the market alone has become a challenge for regulators. Between 2017 and 2020, more than 62,000 supplement notifications were submitted to the Chief Sanitary Inspectorate (GIS), while the number of products listed in official registers exceeded 29,000.</p>



<p id="ember2885">At the same time, authorities increasingly pointed to systemic weaknesses in the existing framework. Under the current rules, a business may place a dietary supplement on the market immediately after submitting a notification to GIS, even if doubts exist regarding the product’s composition or classification. The authorities may initiate explanatory proceedings, but the product can still remain commercially available during the investigation. In practice, this system has often been criticized for providing insufficient preventive control and allowing potentially problematic products to circulate before any meaningful assessment takes place.</p>



<p id="ember2886">Another major concern involved the widespread use of aggressive advertising strategies. For years, the dietary supplements industry has been accused of blurring the line between supplements and medicinal products. Many advertisements indirectly suggested therapeutic effects or implied that supplements could substitute proper medical treatment or balanced nutrition. Regulators and pharmaceutical companies repeatedly argued that existing penalties were too low to deter large market participants from engaging in questionable promotional practices.</p>



<p id="ember2887">The lack of a centralized digital supervision system also contributed to inefficiencies. The notification process relied partly on outdated administrative mechanisms, resulting in difficulties with document verification, inconsistent communication, and lengthy proceedings. The new amendment seeks to address these concerns through digitalization, stricter procedural obligations, and substantially higher financial sanctions.</p>



<p id="ember2888">One of the most visible changes introduced by the reform is the mandatory use of the e-Sanepid platform for all supplement notifications. Until now, notifications could be submitted either electronically or in paper form, and businesses had some flexibility regarding the form and timing of submission. Under the new rules, however, the process becomes fully digitized. Notifications will only be accepted through the e-Sanepid system and will require either a qualified electronic signature or a trusted electronic profile.</p>



<p id="ember2889">This change may appear largely technical at first glance, but in reality it significantly increases the formalization of the entire notification process. For large companies with developed compliance departments, adapting to electronic communication systems is unlikely to create serious difficulties. Smaller businesses, however, may face operational and financial challenges connected with digital authentication tools, procedural monitoring, and document management requirements.</p>



<p id="ember2890">The amendment also changes the moment at which the notification obligation arises. Previously, the law referred both to products already introduced to the market and those merely intended for future introduction. The new wording removes the reference to “intended introduction,” meaning that the obligation will arise only once the product is actually being placed on the market. Although this clarification simplifies the legal interpretation of the obligation, it also narrows the flexibility businesses previously enjoyed when planning product launches.</p>



<p id="ember2891">Perhaps the most consequential aspect of the reform concerns explanatory proceedings and scientific opinions. Under the current framework, businesses could effectively delay proceedings indefinitely by postponing the submission of required scientific documentation. While the law imposed certain deadlines on the authorities themselves, it did not establish sufficiently strict obligations for the notifying entity. This created situations where proceedings remained unresolved for years, significantly limiting the effectiveness of supervision.</p>



<p id="ember2892">The amendment introduces a much stricter procedural regime. Once GIS requests a scientific opinion regarding a product’s classification or compliance, the business will have only 14 days to submit an application to a scientific institution or to the President of the Office for Registration of Medicinal Products. Furthermore, the scientific opinion itself must generally be issued within six months, with an absolute maximum period of twelve months in exceptional cases.</p>



<p id="ember2893">The most significant innovation is the introduction of a legal presumption against the entrepreneur. If the entity fails to submit the application for an opinion within the required 14-day period, the law will automatically presume that the proposed classification of the product is incorrect and that the product does not meet the requirements applicable to its category. In practical terms, procedural inactivity itself may lead to negative legal consequences.</p>



<p id="ember2894">This fundamentally changes the balance between businesses and regulatory authorities. Previously, delaying the process often worked in favor of companies by allowing products to remain on the market while proceedings continued. Under the new rules, inaction may immediately weaken the entrepreneur’s legal position. Businesses will therefore need to implement much stricter internal monitoring systems to ensure compliance with procedural deadlines.</p>



<p id="ember2895">The amendment additionally prohibits businesses from circumventing the procedure by repeatedly submitting notifications for identical products. Once proceedings are initiated, companies will no longer be able to submit another notification concerning a product with the same qualitative and quantitative composition. Similarly, withdrawing a notification will not allow the entrepreneur to restart the process with the same formula at a later stage. These restrictions are intended to eliminate procedural abuse and prevent companies from avoiding regulatory scrutiny through repeated filings.</p>



<p id="ember2896">Another major reform concerns transparency and the expansion of the public product register maintained within the SEPIS system. The current register already contains certain information regarding notified products, but the scope of publicly available data remains relatively limited. The new system significantly broadens the amount of information accessible to consumers and competitors alike.</p>



<p id="ember2897">Under the amendment, the register will include the product name, form of the product, qualitative composition, information regarding active substances, details concerning explanatory proceedings, and information about prohibited ingredients. Although quantitative composition data and certain identifying information regarding the reporting entity will remain confidential, the reform nevertheless represents a substantial increase in market transparency.</p>



<p id="ember2898">From the consumer protection perspective, this may be viewed as a positive development. Consumers will gain easier access to information about supplement composition and regulatory status, potentially allowing for more informed purchasing decisions. However, from the business perspective, the new transparency rules create considerable reputational risks. Information regarding ongoing explanatory proceedings may become publicly visible long before any final administrative decision is issued. As a result, companies may face reputational damage even in situations where no violation is ultimately confirmed.</p>



<p id="ember2899">The reform also updates the broader inspection framework to align Polish law with Regulation (EU) 2017/625 on official controls. Although the regulation has already been directly applicable across the European Union since 2019, several references in Polish legislation still pointed to repealed EU acts. The amendment therefore modernizes the legal terminology and adapts national provisions to the currently binding European framework.</p>



<p id="ember2900">Importantly, however, the changes do not significantly expand the substantive powers of sanitary authorities. The amendment primarily introduces terminological adjustments, extending references from “official food controls” to “official controls and other official activities.” Sanitary authorities will continue to possess extensive powers during inspections, including access to facilities, examination of production processes and documentation, and collection of samples for laboratory testing.</p>



<p id="ember2901">The reform does, however, expand the situations in which businesses must bear the costs of inspections and administrative activities. In addition to existing obligations related to violations, follow-up inspections, and border sanitary controls, businesses will now also be required to cover costs associated with official activities performed at their own request, such as the issuance of certain documents. While this change may appear relatively modest compared to other parts of the reform, it nevertheless contributes to the overall increase in operational costs for market participants.</p>



<p id="ember2902">One of the most controversial elements of the amendment concerns advertising and marketing practices. The reform significantly broadens the scope of administrative liability related to the promotion and presentation of dietary supplements. Previously, penalties focused primarily on incorrect product labeling. Under the new rules, liability will explicitly extend to advertising, online promotion, social media activities, and the overall presentation of products.</p>



<p id="ember2903">Most importantly, the amendment introduces severe sanctions for advertising or presenting a supplement before notifying GIS. This is likely to have a major impact on digital marketing strategies commonly used in the supplements industry. Influencer campaigns, online pre-launch promotions, teaser advertisements, and social media product announcements may all potentially fall within the scope of the new sanctions if conducted before formal notification.</p>



<p id="ember2904">The amendment also reinforces existing prohibitions against suggesting that a balanced diet cannot provide sufficient nutrients or implying medicinal properties of supplements. Although these prohibitions already existed under current law, the reform significantly strengthens enforcement mechanisms by attaching much higher financial penalties to violations.</p>



<p id="ember2905">Indeed, the increase in administrative penalties represents one of the most dramatic aspects of the reform. Under the current framework, the maximum administrative fine generally amounts to thirty times the average monthly salary. The amendment raises this threshold to one hundred times the average salary, increasing potential penalties by more than 330 percent.</p>



<p id="ember2906">Based on current economic indicators, maximum fines could exceed PLN 800,000. Such amounts are clearly intended to function as genuinely deterrent sanctions rather than symbolic administrative measures. For large corporations with extensive marketing operations, these penalties may significantly alter risk calculations related to aggressive advertising or borderline compliance practices.</p>



<p id="ember2907">For businesses operating in the supplements sector, the cumulative impact of these changes may be substantial. Compliance costs are likely to increase considerably. Companies may need to invest in legal advisory services, digital infrastructure, scientific assessments, employee training, and enhanced compliance monitoring systems. Marketing departments in particular will face increased scrutiny and will need to carefully verify advertising content before publication.</p>



<p id="ember2908">The reform may also contribute to market consolidation. Large, well-established companies are generally better positioned to absorb increased compliance costs and adapt to stricter regulatory requirements. Smaller businesses, startups, and niche supplement brands may struggle with the financial and administrative burden created by the new framework. As a result, the amendment could unintentionally reduce market diversity and strengthen the competitive position of major industry players.</p>



<p id="ember2909">From the perspective of public authorities, the reform aims to improve the efficiency and credibility of food safety supervision. Digitalization through e-Sanepid and SEPIS is expected to accelerate administrative processes, improve data analysis capabilities, and strengthen market oversight. The introduction of strict procedural deadlines should also reduce the risk of excessively lengthy proceedings and administrative disputes.</p>



<p id="ember2910">At the same time, the implementation of these systems will require significant investments in technological infrastructure and administrative capacity. The effectiveness of the reform will therefore depend not only on the wording of the legislation itself, but also on the practical ability of GIS and related institutions to manage the new digital environment efficiently.</p>



<p id="ember2911">Ultimately, the amendment does not formally transform dietary supplements into products requiring prior authorization before market entry. Businesses will still be able to introduce supplements through a notification-based system rather than a licensing procedure. Nevertheless, the practical reality of operating in the sector is likely to change considerably.</p>



<p id="ember2912">The reform substantially increases the procedural obligations imposed on businesses, strengthens enforcement tools available to authorities, raises financial exposure connected with non-compliance, and introduces far greater transparency into the market. While these changes may improve consumer protection and market oversight, they also create new operational and reputational risks for entrepreneurs.</p>



<p id="ember2913">For companies active in the supplements industry, the coming months may therefore become a critical period of preparation. Businesses that fail to adapt quickly to the new regulatory environment may face not only financial penalties, but also significant disruptions to their commercial operations and marketing strategies.</p>
<p> </p>


<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/">Dietary Supplements Under Tightened Scrutiny: How the 2026 Reform Could Reshape the Polish Market</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/dietary-supplements-under-tightened-scrutiny-how-the-2026-reform-could-reshape-the-polish-market/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Well-established drugs – the procedure  of well established use</title>
		<link>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/well-established-drugs-the-procedure-of-well-established-use/</link>
					<comments>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/well-established-drugs-the-procedure-of-well-established-use/#respond</comments>
		
		<dc:creator><![CDATA[jakub]]></dc:creator>
		<pubDate>Wed, 21 Jan 2026 17:29:10 +0000</pubDate>
				<category><![CDATA[PHARMACEUTICAL, HEALTHCARE & LIFE SCIENCES LAW]]></category>
		<category><![CDATA[Pharmaceutical Law]]></category>
		<category><![CDATA[Well-established drugs]]></category>
		<guid isPermaLink="false">https://www.kg-legal.eu/?p=8572</guid>

					<description><![CDATA[<p>Publication date: January 21, 2026 Every drug introduced to the EU market must obtain a permit from the competent authority. In Poland, this is the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. EU regulations included in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on [&#8230;]</p>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/well-established-drugs-the-procedure-of-well-established-use/">Well-established drugs – the procedure  of well established use</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><strong><mark style="background-color:rgba(0, 0, 0, 0)" class="has-inline-color has-vivid-cyan-blue-color">Publication date: January 21, 2026</mark></strong></p>



<p>Every drug introduced to the EU market must obtain a permit from the competent authority. In Poland, this is the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. EU regulations included in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, implemented into Polish law by the Act of 6 September 2001 &#8211; Pharmaceutical Law provide for several procedures enabling drug registration, one of which is the so-called <strong><u>well-established medicine procedure</u></strong> (WEU). This is a special procedure for obtaining marketing authorization for medicines containing active substances with <strong>well-established medical use, i.e., medicinal substances known and systematically used in the EU for at least 10 years</strong>. The most important difference with this procedure is that <strong>there is no need to submit new clinical and pre-clinical studies, and the application can be based on available scientific studies </strong>that confirm the effectiveness and safety of the substance.</p>



<span id="more-8572"></span>



<p>Most often, this procedure applies to herbal medicines and medicines containing commonly used substances that were already in use before the introduction of the drug registration requirement – examples include medicines containing paracetamol or aspirin.</p>



<h2 class="wp-block-heading"><strong>Administrative and documentation requirements</strong></h2>



<p>Article 10 paragraph 1 of the Pharmaceutical Law governs the general requirements of an application for marketing authorization for a medicinal product, which should include:</p>



<ol class="wp-block-list">
<li>name and address of the responsible entity, manufacturer or importer;</li>



<li>name of the medicinal product;</li>



<li>detailed quantitative and qualitative data of the active substance or active substances and other substances relating to the medicinal product and their common names, and in their absence – chemical names;</li>



<li>the pharmaceutical form, strength and route of administration and shelf life of the medicinal product, as well as environmental data related to the destruction of the medicinal product, if necessary and resulting from the properties of the product.</li>
</ol>



<p>Pursuant to paragraph 2, the application shall be accompanied by:</p>



<ol class="wp-block-list">
<li>description of the manufacture of the medicinal product;</li>



<li>description of the control methods used in the manufacturing process;</li>



<li>written confirmation by the manufacturer of the medicinal product that it has verified, through an audit, compliance with the requirements of Good Manufacturing Practice by the manufacturer of the active substance at the place where it conducts its manufacturing activities;</li>



<li>information on special requirements for the storage of the medicinal product, its dispensing to patients and the disposal of the expired product, together with an assessment of the environmental risk associated with the medicinal product and a description of methods to reduce this risk;</li>



<li><strong>results, summaries and research reports:</strong><ol><li>pharmaceutical: physicochemical, biological or microbiological,</li></ol><ol><li><strong>non-clinical: pharmacological and toxicological,</strong></li></ol>
<ol class="wp-block-list">
<li><strong>clinical</strong></li>
</ol>
</li>
</ol>



<p>&#8211; together with a quality overall summary, a non-clinical overview and a non-clinical summary, and a clinical overview and a clinical summary;</p>



<ul class="wp-block-list">
<li>a summary description of the pharmacovigilance system used by the marketing authorisation holder, including:<ul><li>a declaration by the marketing authorisation holder (submitted under penalty of perjury) that the marketing authorisation holder has the services of a qualified person responsible for monitoring the safety of medicinal products,</li></ul><ul><li>a list of the Member States of the European Union or the EFTA Member States in which the person referred to in point a resides and performs his or her duties,</li></ul><ul><li>a declaration by the marketing authorisation holder that it has the necessary resources to fulfil its obligations regarding the pharmacovigilance of medicinal products,</li></ul><ul><li>contact details of the person referred to in point a,</li></ul>
<ul class="wp-block-list">
<li>an indication of the place where the full description of the pharmacovigilance system for medicinal products referred to in Article 36g paragraph 1 point 4 is available for inspection;</li>
</ul>
</li>



<li>a risk management plan for the use of a medicinal product;</li>



<li>in the case of clinical trials conducted outside the territory of the European Union Member States or EFTA Member States, a statement that the trials meet the ethical requirements set out in Regulation 536/2014;</li>



<li>declarations signed by the experts preparing the overall quality summary, the non-clinical review and non-clinical data summary, and the clinical review and clinical summary that they possess the necessary technical or professional qualifications, as described in the attached curriculum vitae;</li>



<li>Summary of Product Characteristics;</li>



<li>templates of primary and secondary packaging presented in descriptive and graphic form, as well as a leaflet, along with a report on its readability;</li>



<li>copies of all authorisations issued by the relevant authorities in the European Union Member States or EFTA Member States or third countries, Summaries of Product Characteristics, summaries of safety data, including data from periodic safety update reports and adverse reaction reports, where available, and copies of package leaflets, where applicable, and copies of all decisions refusing to grant an authorisation and the reasons for such decisions;</li>



<li>a list of the European Union Member States and EFTA Member States where an application for a permit is being considered and, where applicable, details of any refusal to grant a permit in any country;</li>



<li>a copy of the authorization to manufacture the medicinal product in the country of manufacture.</li>
</ul>



<p>As can be seen, any entity wishing to market a medicinal product must have extensive documentation to ensure its safe use after marketing authorization. The template for applications submitted to the Polish Office was published in the Regulation of the Minister of Health of January 10, 2014, regarding the template for applications for marketing authorization for medicinal products (consolidated text: Journal of Laws of 2018, item 593).</p>



<p>With regard to the application submitted under the WEU procedure, significant differences are introduced by Article 16 of the Act, according to which <strong>the marketing authorisation holder is not obliged to present the results of non-clinical or clinical trials if:</strong></p>



<ul class="wp-block-list">
<li>the active substance or substances of the medicinal product have <strong>a well-established medical use;</strong></li>



<li><strong>in the territory of a Member State of the European Union or an EFTA Member State;</strong></li>



<li><strong>for a period of at least 10 years,</strong> counting from the first systematic and documented use of this substance in a medicinal product and recognized efficacy and an acceptable level of safety.</li>
</ul>



<p>In this case, the results of non-clinical or clinical studies <strong>are replaced or supplemented</strong> <strong>publications from the scientific literature, and the application must be accompanied by a justification </strong>prepared by an expert regarding the use of scientific literature in accordance with the requirements set out in Annex I.</p>



<p>The publications to be submitted must include the full scope of non-clinical and clinical trial results required for new medicinal products. Furthermore, the wording of Article 16 of the Act contradicts Article 10a of the Directive, which only refers to the replacement of scientific studies with publications, not to their replacement or supplementation.</p>



<h2 class="wp-block-heading"><strong>Criteria for granting a permit</strong></h2>



<p>The above-mentioned conditions for applying the WEU procedure leave considerable room for interpretation and discretion in the issuance of marketing authorizations for medicinal products. Consequently, EU and national authorities have issued numerous guidelines on this topic.</p>



<p>Until March 30, 2007, detailed requirements for the WEU procedure were specified in the Regulation of the Minister of Health of January 16, 2003, regarding documentation of medicinal product test results, including veterinary medicinal products, and expert reports, which was repealed with the amendment to the Pharmaceutical Law. Currently, Polish regulations do not provide a binding interpretation of the concept of a substance with a well-established medical use.</p>



<p>The criteria for applying this concept can be found <strong>in Annex I to the Directive </strong>, according to which the following principles apply to demonstrate well-established medicinal use:</p>



<p>a/ The factors that should be taken into account in order to recognize the well-established medical use of the ingredients of medicinal products are as follows:</p>



<p>&#8211; how long a given substance has been used,</p>



<p>&#8211; the quantitative aspect of the use of a given substance,</p>



<p>&#8211; the degree of scientific interest in a given substance (as reflected in the published scientific literature) and</p>



<p>&#8211; consistency of scientific assessments.</p>



<p>b/ The documentation submitted by the applicant should cover all aspects of the safety and/or efficacy assessment and must include or refer to <strong>a review of the relevant literature,</strong> including pre- and post-marketing studies and published scientific literature on experience gained, in the form of epidemiological studies, and in particular comparative epidemiological studies. <strong>All documentation, both favorable and unfavorable, must be provided.</strong> In accordance with the provisions on &#8220;well-established medical use,&#8221; it is particularly necessary to clarify that &#8220;bibliographic references&#8221; to other sources of evidence (post-marketing studies, epidemiological studies, etc.), and not just data relating to tests and trials, can serve as valid evidence of the product&#8217;s safety and efficacy if the application satisfactorily explains and justifies the use of these sources of information.</p>



<p>c/ Particular attention must be paid to any missing information and an explanation must be provided as to why demonstration of an acceptable level of safety and/or efficacy can be supported despite the absence of some studies.</p>



<p>d/ Non-clinical and/or clinical reviews must clarify <strong>the relevance of any data submitted </strong>that relate to a product other than the product intended for marketing (so-called bridging data). A decision must be made as to whether the investigational product can be considered similar to the product for which marketing authorization has been applied for, despite existing differences.</p>



<p>e/ Post-marketing experience with other products containing the same ingredients is particularly important and the applicant should place special emphasis on this issue.</p>



<p>Furthermore, in July 2019, <strong>the European Commission issued guidance for applicants for marketing authorizations </strong>(Volume 2A, Chapter 1), which also addresses this procedure. The following indications follow from this guidance.</p>



<p>The Commission stressed that applications submitted under Article 10a of the Directive should not lower the level of safety and efficacy that a product with a well-established substance must also meet.</p>



<p>With respect to advanced therapy medicinal products (ATMPs), the Commission has determined that applications under this procedure are only permissible to the extent that the published scientific literature is relevant and sufficient to demonstrate the safety and efficacy profile of the medicinal product. Due to the specific nature of the ATMP manufacturing process, an application under this procedure will be admissible only exceptionally, provided that the manufacturing process for the product covered by the application is identical to the manufacturing process already described in the literature.</p>



<p>It is also worth noting that the term &#8220;medical use&#8221; does not necessarily mean use as an approved medical product, but evidence of the medicinal activity of a given substance must be provided. The 10-year period referred to in the regulations, in the case of a substance used in products authorised for marketing, does not have to cover the entire period during which a given country was a member of the EU or EFTA &#8211; this period also includes the years in which the product was authorised before the country joined the organisation in question.</p>



<p>The term &#8220;well-established use&#8221; refers to the use of a substance for a specific therapeutic purpose &#8211; if a well-known substance is to be used for a completely new therapeutic purpose for which no well-established use can be applied, it will not be possible to use this procedure.</p>



<p>It is the applicant&#8217;s responsibility to provide a detailed description of the strategy used to search for published literature and the rationale behind the selections made. The term &#8220;published&#8221; literature means that the text must be freely available in the public domain and published by a reputable, preferably peer-reviewed, source. Full texts of the research studies must be included in the application, along with any necessary translations.</p>



<p><strong>European Medicines Agency </strong>(EMA) has also issued guidelines on this topic.</p>



<p>It is the applicant&#8217;s responsibility to demonstrate that the active substance contained in the medicinal product for which the application is submitted is identical to the substance described in the literature and to provide appropriate bridging data. Any studies submitted must support the efficacy and safety of the active substance.</p>



<p>The Agency stated that the applicant should submit a tabulated summary of data to support the assessment, including at least the following details:</p>



<ul class="wp-block-list">
<li>Comprehensive information on specific products (formulas that have been used in efficacy and safety studies reported in the literature)</li>



<li>Justification for the studies and literature included to support the judgement that the product studied in the literature can be considered similar to the product for which marketing authorisation is being sought.</li>



<li>Which of the attached literature is considered crucial to demonstrate the effectiveness and safety of a given substance for a specific therapeutic purpose?</li>
</ul>



<p>For specific types of substances and products, EMA has also issued detailed guidance on the requirements for bridging data used to establish the well-established use of a specific substance.</p>



<p>Comparison of active substances in given products should be based on one or more of the following criteria:</p>



<ul class="wp-block-list">
<li>comparison of the qualitative and quantitative composition of the product;</li>



<li>comparison of critical quality attributes;</li>



<li>comparison of dissolution data;</li>



<li>comparison of physicochemical properties;</li>



<li>comparative in vitro release or permeation studies for a locally acting product;</li>



<li>comparative bioavailability (PK) studies;</li>



<li>clinical justification for the lack of comparative bioavailability studies.</li>
</ul>



<p>Finally, it is worth emphasizing that if a medicinal product is authorized for the market under the WEU procedure, it may constitute a reference product when submitting applications for authorization to market equivalent products (as stated by the CJEU in its judgment of 23 October 2014 in case C-104/13).</p>



<p>Sources:</p>



<ol class="wp-block-list">
<li>Act of 6 September 2001 &#8211; Pharmaceutical Law (consolidated text: Journal of Laws of 2025, item 750, as amended).</li>



<li><em>Pharmaceutical law. Commentary, 2nd edition,</em> ed. M. Kondrat, Warsaw 2016.</li>



<li>Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 2001, p. 67, as amended).</li>



<li>Annex I to the above-mentioned Directive</li>



<li>European Commission Guidelines for Applicants (Volume 2A: Marketing Authorisation Procedures. Chapter 1: Marketing Authorisations)</li>



<li><a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers#section-9-well-established-use-78013">https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers#section-9-well-established-use-78013</a></li>
</ol>
<p>Artykuł <a href="https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/well-established-drugs-the-procedure-of-well-established-use/">Well-established drugs – the procedure  of well established use</a> pochodzi z serwisu <a href="https://www.kg-legal.eu">KIELTYKA GLADKOWSKI LEGAL | CROSS BORDER POLISH LAW FIRM RANKED IN THE LEGAL 500 EMEA SINCE 2019</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.kg-legal.eu/info/pharmaceutical-healthcare-life-sciences-law/well-established-drugs-the-procedure-of-well-established-use/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
